Treatment of collagen-induced arthritis using immune modulatory properties of human mesenchymal stem cells

Cell Transplantation

Volumn 25, Issue 6, 2016, Pages 1057-1072

  Park, Kyu Hyung ^a   Mun, Chin Hee ^a   Kang, Mi Il ^a   Lee, Sang Won ^a   Lee, Soo Kon ^a   Park, Yong Beom ^a  

^a Yonsei University   (South Korea)

Author keywords

Immune modulation; Mesenchymal stem cells (MSCs); Regulatory T cells (Tregs); Rheumatoid arthritis (RA)

Indexed keywords

COLLAGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; METHOTREXATE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; CYTOKINE; DNA BINDING PROTEIN; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTOR; TRANSCRIPTION FACTOR; ZFPN1A2 PROTEIN, MOUSE;

ADIPOSE DERIVED STEM CELL; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; DBA 1 MOUSE; HISTOLOGY; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; ADIPOSE TISSUE; ANIMAL; ARTHRITIS, EXPERIMENTAL; BLOOD; BONE MARROW CELL; CYTOLOGY; FEMALE; FETUS BLOOD; IMMUNOLOGY; INFLAMMATION; JOINT; MESENCHYMAL STROMA CELL; METABOLISM; NEWBORN; PATHOLOGY; TIME FACTOR;

ADIPOSE TISSUE; ADULT; ANIMALS; ARTHRITIS, EXPERIMENTAL; BONE MARROW CELLS; CYTOKINES; DNA-BINDING PROTEINS; FEMALE; FETAL BLOOD; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; INFANT, NEWBORN; INFLAMMATION; INFLAMMATION MEDIATORS; JOINTS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; TRANSCRIPTION FACTORS;

EID: 84973149426     PISSN: 09636897     EISSN: 15553892     Source Type: Journal    
DOI: 10.3727/096368915X687949     Document Type: Article

References (45)

1. Akimova, T.; Beier, U.H.; Wang, L.; Levine, M.H.; Hancock, W.W. Helios expression is a marker of T cell activation and proliferation. PLoS One 6(8): e24226; 2011.
2. Augello, A.; Tasso, R.; Negrini, S.M.; Cancedda, R.; Pennesi, G. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum. 56(4): 1175-1186; 2007.
3. Brand, D.D.; Latham, K.A.; Rosloniec, E.F. Collageninduced arthritis. Nat. Protoc. 2(5): 1269-1275; 2007.
4. Camps, M.; Ruckle, T.; Ji, H.; Ardissone, V.; Rintelen, F.; Shaw, J.; Ferrandi, C.; Chabert, C.; Gillieron, C.; Francon, B.; Martin, T.; Gretener, D.; Perrin, D.; Leroy, D.; Vitte, P.A.; Hirsch, E.; Wymann, M.P.; Cirillo, R.; Schwarz, M.K.; Rommel, C. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat. Med. 11(9): 936-943; 2005.
5. Chen, B.; Hu, J.; Liao, L.; Sun, Z.; Han, Q.; Song, Z.; Zhao, RC. Flk-1mesenchymal stem cells aggravate collageninduced arthritis by up-regulating interleukin-6. Clin. Exp. Immunol. 159(3): 292-302; 2010.
6. Chen, F. C; Tuan, R.S. Mesenchymal stem cells in arthritic diseases. Arthritis Res. Ther. 10(5): 223; 2008.
7. Choi, E.W.; Shin, I.S.; Park, S.Y.; Park, J.H.; Kim, J.S.; Yoon, E.J.; Kang, S.K.; Ra, J.C.; Hong, S.H. Reversal of serologic, immunologic, and histologic dysfunction in mice with systemic lupus erythematosus by long-term serial adipose tissue-derived mesenchymal stem cell transplantation. Arthritis Rheum. 64(1): 243-253; 2012.
8. Ciccocioppo, R.; Bernardo, M.E.; Sgarella, A.; Maccario, R.; Avanzini, M.A.; Ubezio, C.; Minelli, A.; Alvisi, C.; Vanoli, A.; Calliada, F.; Dionigi, P.; Perotti, C.; Locatelli, F.; Corazza, G.R. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn’s disease. Gut 60(6): 788-798; 2011.
9. Connick, P.; Kolappan, M.; Crawley, C.; Webber, D.J.; Patani, R.; Michell, A.W.; Du, M.Q.; Luan, S.L.; Altmann, D.R.; Thompson, A.J.; Compston, A.; Scott, M.A.; Miller, D.H.; Chandran, S. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: An open-label phase 2a proof-of-concept study. Lancet Neurol. 11(2): 150-156; 2012.
10. Curotto de Lafaille, M.A.; Lafaille, J.J. Natural and adaptive foxp3+ regulatory T cells: More of the same or a division of labor? Immunity 30(5): 626-635; 2009.
11. Curtis, J.R.; Xi, J.; Patkar, N.; Xie, A.; Saag, K.G.; Martin, C. Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum. 56(12): 4226-4227; 2007.
12. Deans, R.J.; Moseley, A.B. Mesenchymal stem cells: Biology and potential clinical uses. Exp. Hematol. 28(8): 875-884; 2000.
13. Djouad, F.; Bouffi, C.; Ghannam, S.; Noel, D.; Jorgensen, C. Mesenchymal stem cells: Innovative therapeutic tools for rheumatic diseases. Nat. Rev. Rheumatol. 5(7): 392-399; 2009.
14. Duijvestein, M.; Vos, A.C.; Roelofs, H.; Wildenberg, M.E.; Wendrich, B.B.; Verspaget, H.W.; Kooy-Winkelaar, E.M.; Koning, F.; Zwaginga, J.J.; Fidder, H.H.; Verhaar, A.P.; Fibbe, W.E.; van den Brink, G.R.; Hommes, D.W. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn’s disease: Results of a phase I study. Gut 59(12): 1662-1669; 2010.
15. Elman, J.S.; Li, M.; Wang, F.; Gimble, J.M.; Parekkadan, B. A comparison of adipose and bone marrow-derived mesenchymal stromal cell secreted factors in the treatment of systemic inflammation. J. Inflamm. (Lond.) 11(1): 1; 2014.
16. English, K.; Mahon, B.P. Allogeneic mesenchymal stem cells: Agents of immune modulation. J. Cell. Biochem. 112(8): 1963-1968; 2011.
17. Gonzalez, M.A.; Gonzalez-Rey, E.; Rico, L.; Buscher, D.; Delgado, M. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum. 60(4): 1006-1019; 2009.
18. Hsiao, S.T.; Asgari, A.; Lokmic, Z.; Sinclair, R.; Dusting, G.J.; Lim, S.Y.; Dilley, R.J. Comparative analysis of paracrine factor expression in human adult mesenchymal stem cells derived from bone marrow, adipose, and dermal tissue. Stem Cells Dev. 21(12): 2189-2203; 2012.
19. Kavanaugh, A.F. B cell targeted therapies: Safety considerations. J. Rheumatol. Suppl. 77: 18-23; 2006.
20. Kim, S.; Heo, J.S.; Kim, H.S.; Kim, H.O. Isolation of mesenchymal stem cells from the mononuclear cells remaining in the bone marrow processing kit. Korean J. Blood Transfus. 21(3): 280-288; 2010.
21. Le Blanc, K.; Frassoni, F.; Ball, L.; Locatelli, F.; Roelofs, H.; Lewis, I.; Lanino, E.; Sundberg, B.; Bernardo, M.E.; Remberger, M.; Dini, G.; Egeler, R.M.; Bacigalupo, A.; Fibbe, W.; Ringden, O.; Developmental Committee of the European Group for Blood and Marrow Transplantation. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 371(9624): 1579-1586; 2008.
22. Le Blanc, K.; Mougiakakos, D. Multipotent mesenchymal stromal cells and the innate immune system. Nat. Rev. Immunol. 12(5): 383-396; 2012.
23. Lee, S.W.; Kim, J.H.; Park, Y.B.; Lee, S.K. Bortezomib attenuates murine collagen-induced arthritis. Ann. Rheum. Dis. 68(11): 1761-1767; 2009.
24. Levings, M.K.; Bacchetta, R.; Schulz, U.; Roncarolo, M.G. The role of IL-10 and TGF-beta in the differentiation and effector function of T regulatory cells. Int. Arch. Allergy Immunol. 129(4): 263-276; 2002.
25. Li, J.; Ezzelarab, M.B.; Cooper, D.K. Do mesenchymal stem cells function across species barriers? Relevance for xenotransplantation. Xenotransplantation 19(5): 273-285; 2012.
26. Liang, J.; Zhang, H.; Hua, B.; Wang, H.; Lu, L.; Shi, S.; Hou, Y.; Zeng, X.; Gilkeson, G.S.; Sun, L. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: A pilot clinical study. Ann. Rheum. Dis. 69(8): 1423-1429; 2010.
27. Liu, Y.; Mu, R.; Wang, S.; Long, L.; Liu, X.; Li, R.; Sun, J.; Guo, J.; Zhang, X.; Guo, J.; Yu, P.; Li, C.; Liu, X.; Huang, Z.; Wang, D.; Li, H.; Gu, Z.; Liu, B.; Li, Z. Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis Res. Ther. 12(6): R210; 2010.
28. MacDonald, G.I.; Augello, A.; De Bari, C. Role of mesenchymal stem cells in reestablishing immunologic tolerance in autoimmune rheumatic diseases. Arthritis Rheum. 63 (9): 2547-2557; 2011.
29. Malgieri, A.; Kantzari, E.; Patrizi, M.P.; Gambardella, S. Bone marrow and umbilical cord blood human mesenchymal stem cells: State of the art. Int. J. Clin. Exp. Med. 3(4): 248-269; 2011.
30. Meyerrose, T.E.; De Ugarte, D.A.; Hofling, A.A.; Herrbrich, P.E.; Cordonnier, T.D.; Shultz, L.D.; Eagon, J.C.; Wirthlin, L.; Sands, M.S.; Hedrick, M.A.; Nolta, J.A. In vivo distribution of human adipose-derived mesenchymal stem cells in novel xenotransplantation models. Stem Cells 25(1): 220-227; 2007.
31. Paulus, H.E. The use of combinations of disease-modifying antirheumatic agents in rheumatoid arthritis. Arthritis Rheum. 33(1): 113-120; 1990.
32. Paulus, H.E. Protocol development for combination therapy with disease-modifying antirheumatic drugs. Semin. Arthritis Rheum. 23(2 Suppl 1): 19-25; 1993.
33. Prevosto, C.; Zancolli, M.; Canevali, P.; Zocchi, M.R.; Poggi, A. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica 92(7): 881-888; 2007.
34. Ryan, J.M.; Barry, F.P.; Murphy, J.M.; Mahon, B.P. Mesenchymal stem cells avoid allogeneic rejection. J. Inflamm. (Lond.) 2: 8; 2005.
35. Scott, D.; Wolfe, F.; Huizinga, T.W. Rheumatoid arthritis. Lancet 376(9746): 1094-1108; 2010.
36. Schnabel, A.; Gross, W.L. Low-dose methotrexate in rheumatic diseases--Efficacy, side effects, and risk factors for side effects. Semin. Arthritis Rheum. 23(5): 310-327; 1994.
37. Schurgers, E.; Kelchtermans, H.; Mitera, T.; Geboes, L.; Matthys, P. Discrepancy between the in vitro and in vivo effects of murine mesenchymal stem cells on T-cell proliferation and collagen induced arthritis. Arthritis Res. Ther. 12(1): R31; 2010.
38. Shi, S.R.; Liu, C.; Taylor, C.R. Standardization of immunohistochemistry for formalin-fixed, paraffin-embedded tissue sections based on the antigen-retrieval technique: From experiments to hypothesis. J. Histochem. Cytochem. 55(2): 105-109; 2007.
39. Singh, J.A.; Furst, D.E.; Bharat, A.; Curtis, J.R.; Kavanaugh, A.F.; Kremer, J.M.; Moreland, L.W.; O’Dell, J.; Winthrop, K.L.; Beukelman, T.; Bridges, S.L., Jr.; Chatham, W.W.; Paulus, H.E.; Suarez-Almazor, M.; Bombardier, C.; Dougados, M.; Khanna, D.; King, C.M.; Leong, A.L.; Matteson, E.L.; Schousboe, J.T.; Moynihan, E.; Kolba, K.S.; Jain, A.; Volkmann, E.R.; Agrawal, H.; Bae, S.; Mudano, A.S.; Patkar, N.M.; Saag, K.G. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. (Hoboken) 64(5): 625-639; 2012.
40. Sohn, H.S.; Heo, J.S.; Kim, H.S.; Choi, Y.; Kim, H.O. Duration of in vitro storage affects the key stem cell features of human bone marrow-derived mesenchymal stromal cells for clinical transplantation. Cytotherapy 15(4): 460-466; 2013.
41. Taylor, A.; Verhagen, J.; Blaser, K.; Akdis, M.; Akdis, C.A. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: The role of T regulatory cells. Immunology 117(4): 433-442; 2006.
42. Thornton, A.M.; Korty, P.E.; Tran, D.Q.; Wohlfert, E.A.; Murray, P.E.; Belkaid, Y.; Shevach, E.M. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J. Immunol. 184(7): 3433-3441; 2010.
43. Wang, J.; Liao, L.; Tan, J. Mesenchymal-stem-cell-based experimental and clinical trials: current status and open questions. Expert Opin. Biol. Ther. 11(7): 893-909; 2011.
44. Zappia, E.; Casazza, S.; Pedemonte, E.; Benvenuto, F.; Bonanni, I.; Gerdoni, E.; Giunti, D.; Ceravolo, A.; Cazzanti, F.; Frassoni, F.; Mancardi, G.; Uccelli, A. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 106(5): 1755-1761; 2005.
45. Zhao, S.; Wehner, R.; Bornhauser, M.; Wassmuth, R.; Bachmann, M.; Schmitz, M. Immunomodulatory properties of mesenchymal stromal cells and their therapeutic consequences for immune-mediated disorders. Stem Cells Dev. 19(5): 607-614; 2010.